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Abstract: Pseudomonas aeruginosa (P. aeruginosa) possesses a plethora of virulence determinants, in-
cluding the production of biofilm, pigments, exotoxins, proteases, flagella, and secretion systems. 
The aim of our present study was to establish the relationship between biofilm-forming capacity, 
the expression of some important virulence factors, and the multidrug-resistant (MDR) phenotype 
in P. aeruginosa. A total of three hundred and two (n = 302) isolates were included in this study. 
Antimicrobial susceptibility testing and phenotypic detection of resistance determinants were car-
ried out; based on these results, isolates were grouped into distinct resistotypes and multiple anti-
biotic resistance (MAR) indices were calculated. The capacity of isolates to produce biofilm was 
assessed using a crystal violet microtiter-plate based method. Motility (swimming, swarming, and 
twitching) and pigment-production (pyoverdine and pyocyanin) were also measured. Pearson 
correlation coefficients (r) were calculated to determine for antimicrobial resistance, biofilm-
formation, and expression of other virulence factors. Resistance rates were the highest for 
ceftazidime (56.95%; n = 172), levofloxacin (54.97%; n = 166), and ciprofloxacin (54.64%; n = 159), 
while lowest for colistin (1.66%; n = 5); 44.04% (n = 133) of isolates were classified as MDR. 19.87% 
(n = 60), 20.86% (n = 63) and 59.27% (n = 179) were classified as weak, moderate, and strong biofilm 
producers, respectively. With the exception of pyocyanin production (0.371 ± 0.193 vs. non-MDR: 
0.319 ± 0.191; p = 0.018), MDR and non-MDR isolates did not show significant differences in 
expression of virulence factors. Additionally, no relevant correlations were seen between the rate of 
biofilm formation, pigment production, or motility. Data on interplay between the presence and 
mechanisms of drug resistance with those of biofilm formation and virulence is crucial to address 
chronic bacterial infections and to provide strategies for their management. 
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1. Introduction 
Pseudomonas aeruginosa (P. aeruginosa) is a motile, non-fermenting Gram-negative 
bacillus with non-fastidious growth requirements, which is ubiquitous in various aquatic 
environments, in addition to being commonly involved in healthcare-associated 
infections (HAIs) [1,2]. P. aeruginosa is considered as an opportunistic pathogen (8–20% of 
hospitalized individuals are colonized), as it is more commonly found in patients affected 
by invasive surgical interventions, immunosuppression (associated with malignancies 
and their treatment, HIV infection), or other underlying diseases (e.g., diabetes) [3–5]. This 
microorganism has been associated with a wide variety of hard-to-treat infections, such 
as ventilator-associated pneumonia (VAP), sepsis, skin and soft tissue infections (linked 
to burn injuries or pressure ulcers), bone and joint infections, otitis externa, and keratitis 
[6,7]; in addition, multisite infections are also fairly common. Pseudomonas spp. are also 
frequent colonizers of the airways in patients affected by cystic fibrosis, contributing to 
acute exacerbations and the progressive decrease in lung function [8]. 
Although P. aeruginosa (and non-fermenters in general) is considered a low-grade 
pathogen, it possesses a plethora of virulence determinants, including its production of 
pigments (pyoverdine, pyocyanine and pyomelanin), exotoxins (such as exotoxins A, S, T 
and U), proteases (leading to tissue destruction), siderophores, lectins, flagella, and 
various secretion systems (most notably the Type III “injectasome”) [9,10]. However, the 
production of biofilm is probably the most important factor in the survival of P. aeruginosa 
in harsh environmental conditions (such as in nosocomial settings, like intensive care 
units [ICUs] and surgical theaters), facilitating the establishment of chronic infections and 
persistence in vivo [11,12]. Biofilms are composed on mono- or multispecies aggregates of 
bacterial communities, various exopolysaccharides (EPS), environmental DNA, and other 
biomolecules (lipids, proteins, carbohydrates) [13]. Biofilms provide protection from sheer 
forces, drying and immune cells, while also leading to the adaptation of P. aeruginosa into 
metabolically-inactive persister cells [14]. In addition to persister (or small colony variant; 
SCV) formation, the chemical composition of biofilms inhibits the diffusion of 
antimicrobials (acting as a pharmacokinetic barrier to these drugs) and 
disinfectants/biocides [15]. Consequently, the minimum inhibitory concentrations (MICs) 
of bacteria embedded in biofilm may be 101–104 times higher, compared to their 
planktonic counterparts [16]. 
The emergence of antimicrobial resistance (AMR) has become a critical issue for 
healthcare professionals worldwide, as their therapeutic armamentarium has become 
severely limited to address infections caused by multidrug-resistant (MDR) bacteria 
[17,18]. As a consequence, infections caused by MDR pathogens are associated with 
increased mortality rates and hospitalization costs, and decreased quality of life (QoL) in 
affected patients [19]. P. aeruginosa possesses intrinsic resistance to a wide range of 
antimicrobials, and due to its pronounced genomic plasticity and rich resistome, it has a 
particular propensity of acquire mechanisms of resistance (through horizontal gene 
transfer) to several, structurally-distinct antimicrobial drugs [9,20]. As a result, P. 
aeruginosa isolates with high-level resistance to fluoroquinolones, aminoglycosides, and 
carbapenems are increasingly common worldwide [21]. The association between biofilm-
forming capacity, virulence factor expression, and the MDR phenotype in pathogenic 
bacteria has been studied extensively [22,23]; however, the topic is still a contentious issue, 
as many authors—using various methodologies and involving different species of 
clinically-relevant bacteria—have come to markedly different conclusions. With this in 
mind, the aim of our present study was to establish the relationship between biofilm-
forming capacity, the expression of some important virulence factors, and the MDR 
phenotype in P. aeruginosa. 
2. Materials and Methods 
2.1. Isolates 
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A total of three hundred and two (n = 302) P. aeruginosa isolates were included in this 
study, which were kindly provided from the strain collections of a Hungarian and Italian 
tertiary care hospital. The study uses a cross-sectional design, with microorganisms that 
were isolated between 1 Janurary 2019 and 1 Janurary 2020., originating from various 
types of clinical specimens, being randomly selected to be included in our experiments. 
During the study, P. aeruginosa ATCC 27853 (MDR isolate, weak biofilm producer) and P. 
aeruginosa PAE 170022 (susceptible isolate, strong biofilm producer) were used as control 
strains, obtained from the American Type Culture Collection (Manassas, VI, USA) [24]. 
Stock cultures were stored at −80 °C in a cryopreservation medium (700 µL trypticase soy 
broth + 300 µL 50% glycerol) until use. 
2.2. Re-Identification of Isolates 
 All isolates included in our study were re-identified as P. aeruginosa before further 
experiments. Re-identification of isolates was carried out using matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Bruker 
Daltonics, Bremen, Germany); to perform the MALDI-TOF assay, bacterial cells from fresh 
overnight cultures on agar plates were transferred to a stainless steel target with a sterile 
toothpick. An on-target extraction was performed by adding 1 µL of 70% formic acid prior 
to the matrix. After drying at room temperature, the cells were covered with 1 µL matrix 
(α-cyano-4-hydroxy cinnamic acid in 50% acetonitrile/2.5% trifluoro-acetic acid; Bruker 
Daltonics, Bremen, Germany). Mass spectrometry analyses were performed by a 
MicroFlex MALDI Biotyper (Bruker Daltonics, Bremen, Germany) in positive linear mode 
across the m/z range of 2 to 20 kDa; for each spectrum, 240 laser shots at 60 Hz in groups 
of 40 shots per sampling area were collected [22]. For analyses of spetra, the MALDI 
Biotyper RTC 3.1 software and the MALDI Biotyper Library 3.1 (Bruker Daltonics. 
Bremen. Germany) were utilized. After analysis, a log(score) value was assigned to all 
isolates, indicating the reliability of MALDI-TOF MS identification. The log(score) values 
were evaluated as follows: a log(score) <1.69 showed unreliable identification, 1.70–1.99 
corresponded to probable genus-level identification, 2.00–2.29 corresponded to reliable 
genus-level identification, while a score ≥2.30 corresponded to reliable species-level 
identification [25]. 
2.3. Antimicrobial Susceptibility Testing, Resistotyping 
Antimicrobial susceptibility testing for respective isolates was carried out using the 
Kirby-Bauer disk diffusion method (Oxoid, Basingstoke, UK), and in subsequent 
experiments (when relevant) with E-tests (Liofilchem, Roseto degli Abruzzi, Italy) on 
Mueller-Hinton agar (MHA) (bioMérieux, Marcy-l’Étoile, France) plates in case of 
ceftazidime (CAZ; 10 µg), cefepime (FEP; 30 µg), imipenem (IMI; 10 µg), meropenem 
(MER; 10 µg), ciprofloxacin (CIP; 5 µg), levofloxacin (LEV; 5 µg), gentamicin (GEN; 10 
µg), and amikacin (AMI; 30 µg), respectively. Colistin (COL) susceptibility was performed 
using the broth microdilution method in cation-adjusted Mueller–Hinton broth (MERLIN 
Diagnostika GmbH, Bremen, Germany). Intermediate results were grouped with and 
reported as resistant [26]. The isolates were grouped into distinct resistotypes based on 
the presence of phenotypic resistance to relevant antimicrobials [27]. Interpretation of the 
results were based on the recommendations of the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) relevant at the time of isolation [28]. Classification of the 
isolates as (MDR; resistance to at least one agent in ≥3 antibiotic groups) was based on 
Magiorakos et al. [29]; in subsequent analyses, isolates were divided as non-MDR and 
MDR. A multiple antibiotic resistance (MAR) index—ranging between 0 and 1—was 
calculated by dividing the total number of detected resistance to antimicrobials for each 
isolate by the total number of tested antimicrobials [27]. 
2.4. Phenotypic Detection of AmpC Overexpression and Carbapenemase Production 
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In CAZ-resistant isolates, the overexpression of AmpC β-lactamase enzymes was 
tested by an agar plate method, where the agar base was supplemented with cloxacillin 
(250 µg/mL); during this assay, the property of cloxacillin—capable of inhibiting the 
effects of AmpC β-lactamases—was used [26,30]. A two-fold difference in CAZ MICs 
(determined by E-tests; Liofilchem, Roseto degli Abruzzi, Italy) with or without the pres-
ence of cloxacillin, was considered as positivity for AmpC overexpression [26,30]. Pheno-
typic screening for carbapenemase-production—performed if MER disk diameters were 
either in the intermediate (23–18 mm) or resistant (<19 mm) categories [28]—was assessed 
by the modified Hodge (cloverleaf) test (MHT), optimized for P. aerugniosa, as previously 
described [31]. In the assay, MER disks (10 µg; Oxoid, Basingstoke, UK) were utilized and 
Escherichia coli ATCC 25922 was used as an indicator organism. 
2.5. Phenotypic Detection of Bacterial Efflux Pumps Contributing to the Drug-Resistant 
Phenotype 
The effect of phenylalanine-arginine β-naphthylamide (PAβN)—a compound with 
well-known efflux pump inhibitory activity—on the susceptibility of tested antimicrobials 
was detected using the agar dilution method described previously [32]. The experiments 
were performed in case of isolates resistant to MER and/or CIP, based on the disk diffu-
sion-based susceptibility tests. During the experiments, the concentration of PAβN was 
40 µg/mL in the agar base; a two-fold decrease in MER and/or CIP MICs (determined by 
E-tests; Liofilchem, Roseto degli Abruzzi, Italy) in the presence of PAβN, compared to the 
MIC values without the inhibitor, was considered as positivity for efflux pump overex-
pression [32]. P. aeruginosa ATCC 27853 was used as a control strain. 
2.6. Biofilm Production 
The capacity of respective P. aeruginosa isolates to produce biofilm was assessed 
using a microtiter-plate based method previously described by Ramos-Vivas et al. [33]. In 
brief, overnight P. aeruginosa cultures (grown on Luria–Bertani [LB] agar) were inoculated 
into 5 mL of Luria-Bertani (LB) broth, and incubated overnight at 37 °C. The following 
day, 180 µL of LB broth and 20 µL of P. aeruginosa suspension (set at 106 CFU/mL) were 
measured onto 96-well flat-bottomed microtiter plates, to a final volume of 200 µL, and 
incubated for 24 h at 37 °C. After the incubation period, the supernatants were discarded 
and the wells were washed three times using 200 µL of phosphate buffered saline (PBS; 
pH at 7.2), to remove planktonic cells that may interfere with the the interpretation of the 
results. After washing, the wells were fixed with 250 µL of methanol (Sigma-Aldrich, St. 
Louis, MO, USA) for 10 min and stained with a 1.0% crystal violet (CV; Sigma-Aldrich, St. 
Louis, MO, USA) solution for 15 min. Subsequently, the CV solution was discarded, and 
the wells were washed three times with purified water to remove excess stain. The con-
tents of the wells were re-suspended in 250 µL of 33% V/V% glacial acetic acid (Sigma-
Aldrich, St. Louis, MO, USA) and absorbance at 570 nm (OD570) was measured using a 
microtiter plate reader. All experiments were carried out in triplicate. The interpretation 
of the results was carried out based on the recommendations of Ansari et al., i.e., isolates 
were classified as weak/non-biofilm producers with OD570 values <0.12, moderate biofilm 
producers with OD570 = 0.12–0.24, and strong biofilm producers with OD570 values >0.24, 
respectively [34]. 
2.7. Motility (Swimming, Swarming, and Twitching) Assays 
For motility assays, bacterial cultures grown overnight were diluted to a density of 
105 CFU/mL and transferred to Petri dishes containing Tryptic Soy Agar (TSA) medium, 
with different concentrations of agar (0.3%, 0.8% and 2% for swimming, swarming, and 
twitching motility, respectively). The bacterial suspension was transferred into the agar 
medium by puncture using a pipette tip (at 1/2 depth for swimming and swarming mo-
tility and at full depth for twitching motility) [35,36]. The plates were then incubated at 37 
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°C for 24 h (swimming and swarming motility) and 48 h (twitching motility). After the 
incubation period, the diameter of the growth zones (mm) were measured; in case of 
swimming and swarming motility, the measurements were made directly, while in case 
of twitching motility, the agar layer was removed and the bottom of the plates were 
stained directly with 0.01% CV solution (Sigma-Aldrich, St. Louis, MO, USA) [35,36]. All 
experiments were carried out in triplicate. 
2.8. Production of Pyoverdine and Pyocyanin Pigments 
An overnight grown bacterial culture was diluted to 105 CFU/mL in TSB, transferred 
to 24-well culture plates (Sarstedt, Nümbrecht, Germany), and incubated at 37 °C for 48 
h. Following incubation, each bacterial suspension was collected in an Eppendorf tube 
and centrifuged at 10,000 RPM. The supernatants were transferred to transparent 96-well 
plates for pyocyanin measurements, while they were transferred to black 96-well plates 
for pyoverdine measurements. The absorbance for pyocyanin (OD686) was measured at λ 
= 686 nm, while the fluorescence of pyoverdine at λex/em = 395/460 nm (EM460 at EX395), using 
a microtiter plate reader [37,38]. All experiments were carried out in triplicate. 
2.9. Statistical Analyses 
Descriptive statistical analysis (including means with ranges and percentages to char-
acterize data) was performed using Microsoft Excel 2013 (Redmond, WA, USA, Microsoft 
Corp.). Independent sample t-tests were performed to compare measurements of OD570 
(for biofilm production), growth zones (for swimming, swarming and twitching motility), 
OD686 (for pyocyanin production) and EM460 (for pyoverdine production) between MDR 
and non-MDR P. aeruginosa isolates. A correlation matrix was calculated to determine the 
association between the measurements (i.e., numerical data OD570, growth zones in mm, 
OD686 and EM460, respectively) corresponding to the expression of virulence-determinants. 
In addition, correlation between the presence of resistance against tested antibiotics and 
biofilm formation was also determined, where isolates received a score of 0/1 depending 
on the susceptibility/resistance to an antimicrobial, and 0/0.5/1, based on the classification 
of the biofilm-forming capacity (weak/moderate/strong) of the isolate, respectively. Based 
on the value of the Pearson-correlation coefficients (r), the relationship between the vari-
ables was determined as follows: of |r| < 0.3 were denoted as weak correlation, 0.3 < |r| 
< 0.5 as moderate correlation, and 0.5 < |r| < 0.85 as strong correlation [39]. Statistical 
analyses were performed with SPSS software version 22 (IBM Corp., Armonk, NY, USA). 
3. Results 
3.1. Antimicrobial Resistance of P. aeruginosa Isolates, Resistotyping 
The antimicrobial resistance levels of the P. aeruginosa isolates included in the study 
were the following: CAZ 56.95% (n = 172), LEV 54.97% (n = 166), CIP 52.64% (n = 159), FEP 
49.34% (n = 149), GEN 33.77% (n = 102), AMI 25.82% (n = 78), MER 23.17% (n = 70), IMI 
21.19% (n = 64), and COL 1.66% (n = 5; MIC> 2 mg/L); overall, 44.04% (n = 133) of isolates 
were classified as MDR. The distribution of the various resistotypes detected among P. 
aeruginosa isolates are presented in Table 1. 
Table 1. Resistotype distribution and MAR indices of respective isolates. 
Resistotypes Resistance Pattern MAR Index 
MDR  
Status 
Ratio of Isolates 
(n, %) 
0 None 0 
non-MDR 
55.96% (n = 169) 
130 (43.05%) 
I CAZ 0.111 1 (0.33%) 
II CAZ, LEV 0.222 7 (2.32%) 
III CAZ, CIP, LEV 0.333 15 (4.97%) 
IV CAZ, FEP, CIP 0.333 4 (1.32%) 
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V CAZ, FEP, LEV 0.333 4 (1.32%) 
VI CAZ, FEP, GEN 0.333 5 (1.66%) 
VII CAZ, FEP, CIP, LEV 0.444 3 (0.99%) 
VIII CAZ, FEP, CIP, LEV, GEN 0.555 
MDR 44.04% (n = 
133) 
5 (1.66%) 
IX CAZ, FEP, CIP, LEV, IMI 0.555 10 (3.31%) 
X CAZ, FEP, CIP, LEV, MER 0.555 10 (3.31%) 
XI CAZ, FEP, CIP, LEV, GEN, IMI 0.666 7 (2.32%) 
XII CAZ, FEP, CIP, LEV, GEN, MER 0.666 7 (2.32%) 
XIII CAZ, FEP, CIP, LEV, IMI, MER 0.666 16 (5.29%) 
XIV CAZ, FEP, CIP, LEV, GEN, AMI 0.666 23 (7.62%) 
XV CAZ, FEP, CIP, LEV, GEN, AMI, IMI 0.777 16 (5.29%) 
XVI CAZ, FEP, CIP, LEV, GEN, AMI, MER 0.777 22 (7.28%) 
XVII CAZ, FEP, CIP, LEV, GEN, AMI, COL 0.777 2 (0.67%) 
XVIII CAZ, FEP, CIP, LEV, GEN, AMI, IMI, MER 0.888 12 (3.97%) 
XIX CAZ, FEP, CIP, LEV, GEN, AMI, IMI, MER, COL 1.000 3 (0.99%) 
3.2. Detection of AmpC Overexpression, Carbapenemase Production, and Efflux Pump 
Overexpression Using Phenotypic Methods 
To ascertain the contribution of various resistance mechanisms in the drug resistance 
of the relevant P. aeruginosa isolates, phenotypic tests were utilized. Using the cloxacillin 
plate-based assay, AmpC overexpression—corresponding to a two-fold decrease in the 
CAZ MICs—was noted in 48.26% (n = 83; 27.48% overall) of isolates; CAZ resistance was 
characteristic to all (83/83) of these isolates, while 61/83, 13/83, and 11/83 were resistant to 
FEP, MER, and IMI, respectively. The MHT test was used to detect for the production of 
carbapenemases: the test was positive in 25.71% (n = 18; 5.96% overall) of cases, when non-
susceptibility to MER (or both) was seen. The effects of efflux pump overexpression (based 
on the PAβN screening agar, demonstrated by the two-fold decrease in MICs in the pres-
ence of the inhibitor) were noted in 31.42% (n = 22; 7.28% overall) with regards to MER 
resistance and in 54.72% (n = 87; 28.8% overall) regarding CIP resistance, respectively. In 
the case of n = 3 isolates AmpC-hyperproduction and MHT-positivity, while in n = 6 iso-
lates, efflux pump overexpression and MHT positivity were noted; in n = 3 isolates, efflux 
pump overexpression, AmpC hyperproduction, and MHT positivity were detected sim-
ultaneously. 
3.3. Biofilm Formation and Expression of Virulence Factors (Pigments, Motility) among Non-
MDR and MDR P. aeruginosa 
Biofilm formation assays were carried out in a microtiter plate-based platform, using 
CV staining. Based on the OD570 measurements, 19.87% (n = 60) of the isolates were 
weak/non-biofilm producers, 20.86% (n = 63) were moderate biofilm producers, while 
59.27% (n = 179) were strong biofilm producers, overall. The distribution of isolates with 
different biofilm-forming capacities did not show pronounced differences among the 
MDR and non-MDR groups (Table 2). Additionally, while numerical differences may be 
seen, MDR and non-MDR isolates did not show significant differences in expression of 
virulence factors (measured via our in vitro experiments), with the exception of pyocyanin 
production (OD686), which was shown to be higher among MDR isolates (0.371 ± 0.193 vs. 
non-MDR: 0.319 ± 0.191) (Table 2). 
The correlation between the presence/absence (denoted as 0 and 1 in the analyses) of 
resistance to relevant antibiotics and biofilm-forming capacity (denoted as 0, 0.5 and 1 in 
the analyses for weak, moderate, and strong biofilm production, respectively) is presented 
in Table 3. Similarly to our previous findings (MDR/non-MDR), biofilm formation did not 
show significant correlation with the existence of resistance to any antibiotic tested, with 
|r| values consistently < 0.3, with the exception of CIP (r = 0.309; p > 0.05) and LEV (r = 
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0.324; p > 0.05). The correlation matrix on the phenotypic expression of biofilm formation 
and other virulence factors is presented in Table 4; no relevant correlations (with |r| values 
consistently < 0.1) were seen between the rate of biofilm formation and pigment produc-
tion or motility. 
Table 2. Biofilm formation and expression of other virulence factors among non-MDR and MDR P. 
aeruginosa. 
  Non-MDR (n = 169) MDR (n = 133) Statistics 
Biofilm formation (OD560) 
(mean ± SD) 
0.333 ± 0.216 0.316 ± 0.200 n.s. (p = 0.634) 
Weak/non-biofilm 
producer (n, %) 
18.34% (n = 31) 21.80% (n = 29) 
n.r. 
Moderate biofilm 
producer (n, %) 
30.77% (n = 52) 8.27% (n = 11) 
Strong biofilm producer 
(n,%)  
50.89% (n = 86) 69.93% (n = 93) 
Swimming motility (mm) 
(mean ± SD) 
29.31 ± 10.99 27.46 ± 10.38 n.s. (p = 0.183) 
Swarming motility (mm) 
(mean ± SD) 
32.05 ± 17.88 32.79 ± 18.49 n.s. (p = 0.728) 
Twitching motility (mm) 
(mean ± SD) 
13.63 ± 7.24 14.23 ± 6.75 n.s. (p = 0.458) 
Pyocyanin production 
(OD686) 
(mean ± SD) 
0.319 ± 0.191 0.371 ± 0.193 p = 0.018 
Pyoverdine production 
(EM460) 
(mean ± SD) 
2012 ± 1132 2064 ± 1124 n.s. (p = 0.774) 
n.s.: not significant; n.r.: not relevant; values in boldface were p < 0.05 
Table 3. Correlation matrix regarding the microbial categories (weak/moderate/strong) based on biofilm formation and 
resistance to antibiotics in P. aeruginosa isolates. 
 CAZ FEP IMI MER CIP LEV GEN AMI COL  
Biofilm 
formation 
0.123 0.134 0.101 0.124  0.309 0.324 0.139 0.113 −0.012 
Pearson-corre-
lation coeffi-
cient (r = ) 
0.231 0.218 0.581 0.564 0.102 0.099 0.567 0.605 0.986 Statistics (p = ) 
Table 4. Correlation matrix regarding the phenotypic expression of biofilm formation and other virulence factors among 
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Swarming 
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4. Discussion, Review of the Literature 
The increasing prevalence of MDR infections globally—especially in non-fermenting 
Gram-negative bacteria—may be considered as one of the hallmarks of the 21st century, 
especially when it comes to the procurement of safe and effective medical care [40,41]. The 
injudicious use of antibiotics and the lack of newly developed antibiotics are important 
hallmarks of this impending crisis [42,43]. Based on the projections of the “Burden of An-
timicrobial Resistance Collaborative Group”, corresponding to the European Union (EU) 
and the European Economic Area (EEA), over 700,000 infections, >33,000 deaths, and 
~900,000 disability-adjusted life years (DALY) were attributable to MDR bacteria, in the 
year 2015 alone [44]. Non-fermenting Gram-negative bacteria extensively contribute to 
the overall infectious disease burden—especially in immunocompromised individuals—
which is now showing an increasing trend of morbidity and mortality (HAIs are associ-
ated with an overall mortality rate of 20–60%), due to the developments in resistance rates 
[45,46]. This has been confirmed by the World Health Organization’s (WHO) published 
report, in which carbapenem-resistant Acinetobacter baumannii complex (CR-AB), car-
bapenem-resistant P. aeruginosa (CR-PA), and carbapenem-resistant and/or ESBL-produc-
ing Enterobacterales were all identified as “critical priority” pathogens for the develop-
ment of novel antibiotics and alternative anti-infective treatment strategies [47]. 
P. aeruginosa—especially under strong selection pressures in nosocomial environ-
ments—has the capacity of becoming resistant to most relevant antimicrobials [9,48]. This 
includes intrinsic non-susceptibility to many orally-available agents (e.g., a chromoso-
mally-encoded AmpC β-lactamase, which may be stably de-repressed), and the acquisi-
tion of novel resistance genes through the means of horizontal gene transfer (i.e., in-
tegrons, plasmids, or transposons), leading to resistance to the four major group of anti-
pseudomonal agents, namely relevant cephalosporins (and cephalosporin/β-lactamase 
combinations), carbapenems, aminoglycosides, respiratory fluoroquinolones (ciprofloxa-
cin, levofloxacin, and moxifloxacin), and colistin [49]. Based on the data from the ECDC 
Surveillance Atlas of Infectious Diseases for 2019, resistance rates in P. aeruginosa ranged 
between 3.5−52.2%, 4.5–52.2%, 0.3–48.9% and 0–55.4% for ceftazidime, fluoroquinolones, 
aminoglycosides, and carbapenems in EU countries, respectively [50]. In addition to these 
genetically-determined resistance mechanisms (leading to the expression of mutated tar-
get proteins or inactivating enzymes, the relevance of so-called “adaptive” mechanisms 
also needs to be discussed; strong biofilm formation and metabolic downregulation to-
wards the emergence of SCVs are difficult to study in vitro, but their relevance in in vivo 
infection dynamics must not be underestimated, as they lead to therapy-resistant, recalci-
trant infections [51]. 
In clinical practice, MDR Pseudomonas infections are most often treated by car-
bapenem antibiotics, as these drugs are often considered the last safe and effective alter-
natives to treatment, especially in some patients (e.g., the elderly), where other drugs 
would be contraindicated due to their toxic adverse events or in cases (e.g., critically ill 
patients) where pathophysiological changes may significantly alter antibacterial pharma-
cokinetics, making the dosing of other drugs difficult [52]. Thus, the growing rate of CR-
PA in nosocomial infections (with rates ranging between 0–60%, showing pronounced 
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geographical differences) is a chilling concept; in a recently published meta-analysis, it 
was found that in addition to a history of carbapenem use, the prior use of piperacil-
lin/tazobactam or vancomycin were all relevant risk factors for the acquisition of CR-PA 
[53,54]. Phenotypic carbapenem resistance is often due to a combination of more than one 
mechanism of resistance, which may be mediated via modifications in the transpeptidases 
(or penicillin-binding proteins; PPB2 and 3) [55], outer membrane impermeability (often 
due to OprD porin deficiency or loss) [56], overexpression of efflux pump systems [57], 
and the production of carbapenemases. Carbapenemases are β-lactamases with versatile 
hydrolytic capabilities; they can hydrolyze penicillins, cephalosporins, monobactams, and 
carbapenems [58]. Based on their biochemical characteristics and substrate profile, car-
bapenemases are classified into serine (including Ambler Class A [KPC], C [AmpC] and 
D [OXA-48-like family]) and metallo-β-lactamases (MBLs; Ambler Class B) [59]. These en-
zymes are often encoded by horizontally-transferable genes, which are often also associ-
ated with resistance determinants to other classes of antimicrobial drugs [60]. Currently, 
the propagation of carbapenemase-producing organisms, especially in non-fermenting 
Gram-negative bacteria, is a public health issue these resistance-determinants may rapidly 
disseminate, leading to outbreaks of bacteria with extensive resistance [61]. While Class 
A and D carbapenemases have also been described, the metallo-β-lactamases blaVIM and 
blaIMP are the most prevalent in Pseudomonas spp. [62,63]. The treatment of CR-PA infec-
tions heavily rely on last-resort agent that are either associated with more serious adverse 
events (colistin), or that are relatively new, with limited clinical experience in these infec-
tions (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, 
plazmomycin) [64]. In addition, the therapy of metallo-β-lactamases is especially difficult, 
as currently there are no β-lactamase-inhibitors authorized for clinical use that would be 
effective against these enzymes. For example, in a study by O’Neall et al., n = 250 car-
bapenem non-susceptible P. aeruginosa isolates were tested for their susceptibility for 
ceftolozane/tazobactam and ceftazidime/avibactam, showing that these drugs presented 
with good in vitro efficacy against these isolates, but only as long as they did not produce 
carbapenemases; on the other hand, isolates carrying blaVIM or blaNDM were resistant to 
these new antibiotic combinations [65]. Thus, it is unsurprising that many clinical studies 
have highlighted that CR–PA infections are associated with worse clinical outcomes, com-
pared to their carbapenem-susceptible counterparts [66]. 
In studies trying to ascertain the relationship between biofilm formation and drug 
resistance, phenotypic or a combination of phenotypic and molecular-based (PCR) meth-
odologies are used, involving a wide variety of isolates from distinct clinical origins 
[67,68]. The majority of these studies have highlighted that around 75–99% of Pseudomonas 
spp. are biofilm producers, including 8–50% being characterized as strong biofilm pro-
ducers [23]. As a part of our study, a large pool (n = 302) of P. aeruginosa isolates from 
diverse geographical and clinical origins were subjected to phenotypic tests to ascertain 
the possible correlation between biofilm-forming capacity, pigment production and mo-
tility (chosen as representative expressions of virulence), and antimicrobial resistance in 
these isolates. In our pool of isolates, resistance rates were the highest for ceftazidime and 
the fluoroquinolones, while >44% was classified as MDR. Over 25% isolates were charac-
terized by the expression of AmpC β-lactamase, ~6% was positive for carbapenemase-
production, and in ~7%, carbapenem non-susceptibility was affected by efflux pump over-
expression, respectively (based on the phenotypic tests applied). Majority of isolates 
(59.27% overall) were strong biofilm producers, both in the MDR and non-MDR groups. 
Based on our results, no relevant correlation was seen between the resistance to individual 
antibiotics—or the presence of the MDR phenotype as a whole—and biofilm-forming ca-
pacity. Similarly—with the exception of pyocyanin production—no association was noted 
for other virulence factors and drug resistance. Based on our experimental data, we also 
did not observe a notable relationship between biofilm formation and other virulence fac-
tors. It is interesting to note that there was no association between the levels of different 
motilities expressed by Pseudomonas; this may be explained by the fact that—although all 
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of these motility strategies have important physiological roles—their differential expres-
sion is needed to accommodate the adaptation of this pathogen to different niches [9,69]. 
Pyocyanin is a blue-green, lipid soluble pigment, which has redox-active properties, 
being a major electron acceptor for molecular O2; the synthesis of this pigment is mediated 
by PhzM (N-methyltransferase) and PhzS (flavin-dependent hydroxylase) [70]. This pig-
ment has been described as an essential factor in the virulence of Pseudomonas, especially 
in skin and soft tissue infection and invasive infections of the lungs. Pyocyanin may often 
be detected in high concentrations in the airway tissues and sputum of CF patients, where 
it contributes to chronic lung infection and bronchiectasis by facilitating mucus overpro-
duction, inhibition of ciliary activity and the α1-protease inhibitor (leading to excess tissue 
injury), and inhibition of IL-2 expression, leading to increased IL-8 release [71]. Pyocyanin 
may also have inhibitory properties on other bacterial species, aiding Pseudomonas in the 
competition in a given ecological niche; among others, this phenomenon was demon-
strated in the decreased diversity of microbial communities in the sputa of patients, where 
pyocyanin concentrations were high [72,73]. Our experiments found that the production 
of pyocyanin was a distinctive hallmark between the MDR and non-MDR group, with 
isolates in the former group showing higher levels of pigment production. During the 
experiments of Fuse et al., reverse-phase high-performance liquid chromatography (RP-
HPLC) was used for the quantitative extraction of pyocyanine in P. aeruginosa; their study 
concluded that MDR (including many MBL-producers) reduced pyocyanine expression, 
compared to the non-MDR group [74]. With similar aims to our study, Gholami et al. in-
cluded 100 P. aeruginosa isolates from clinical and environmental origins; they found 
blaTEM and blaSHV positivity in 92%/16% and 20/6% of the isolates, respectively, with 
clinical isolates having higher proclivity to becoming MDR. 70% and 28% (with 98% and 
70% of these isolates carrying the algD and algU genes) of these isolates were classified as 
strong biofilm producers; however, no association between the MDR phenotype and bio-
film-formation was found [75]. Yamani et al. utilized phenotypic and genotypic methods 
to characterize 66 Pseudomonas isolates: in their study, 53.03%/24.24%/22.73% of isolates 
were classified as strong/moderate/weak biofilm producers, respectively. By measuring 
the expression levels of 10 virulence genes (exoT, exoS, exoU, phZ, las and pil genes), they 
found that—although all associated genes were present in all isolates—all biofilm and 
virulence-associated genes were significantly upregulated in non-MDR isolates, demon-
strating an inverse correlation [76]. The experiments of Kamali et al. included 80 isolates, 
from which 50% were characterized as moderate or strong biofilm producers; they found 
that 87.5% possessed all three genes relevant for biofilm formation (algD, pslD, and pelF) 
and a positive correlation between biofilm formation and the presence of these genes, 
while no association was noted between biofilm formation and drug resistance [77]. 
Jabalameli et al. studied the carriage of Type III secretory toxin-encoding genes and their 
cytotoxic action on A549 human lung cancer cell lines in 96 clinical P. aeruginosa isolates, 
finding that the carriage of exoT, exoY, exoU, and exoS were 100%, 95%, 64.5%, and 29%, 
respectively. 47%/26% of the isolates were strong/moderate biofilm producers, respec-
tively; no association was seen between resistance phenotype and biofilm formation, and 
interestingly, neither between the presence of toxin-encoding genes and the extent of toxic 
effects seen on the cell lines [78]. 
In contrast, the study of Abidi et al., which included 22 P. aeruginosa isolated from 
keratitis, concluded that strong biofilm producers were significantly more common 
among MDR isolates [79]. Choy et al. involved 77 Pseudomonas isolates originating from 
keratitis of contact lens and non-contact lens origin; while no correlation was seen be-
tween drug resistance and biofilm formation, the presence of the exoU gene (mostly found 
in contact lens-related isolates) and strong biofilm formation showed strong positive cor-
relations [80]. In a study involving 74 P. aeruginosa from the sputum of CF and non-CF 
patients, Perez et al. noted that no differences in biofilm formation were observed among 
isolates from different patient origins (although 85.7% of CF isolates presented as the mu-
coid phenotypic variant), MBL positivity showed strong association with strong biofilm 
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production [81]. In a study involving n = 190 isolates, Eladawy et al. found no relevant 
associations between antimicrobial resistance, biofilm formation, and the presence of 
genes encoding for selected virulence factors (i.e., alignate, biofilm, exotoxin A, L-orni-
thine monooxygenase, phospholipases T3SS, proteases, and pyocyanin) [82]. da Costa 
Lima et al. used molecular methods to assess the correlation between the presence of 
quorum sensing (QS) genes and biofilm formation in 40 P. aeruginosa isolates: while all 
isolates carried these genes, no association was found with the capacity to produce biofilm 
[83]. Subedi et al. included 22 isolates from eye infections and CF sputa for testing: the 
prevalence of exoU was 61.5%, and isolates carrying exoU showed higher rates of re-
sistance and higher rates of mutations in the quinolone resistance determining region 
(QRDR) [84]. In a study involving 78 clinical and environmental isolates, Karami et al. 
found MDR rates of 48.7% and a strong positive association was shown between biofilm-
formation and the MDR status [85]. Bahador et al. noted a positive association between 
biofilm formation and the presence of the exoU and exoS genes (36.6% and 55.7%, respec-
tively), but not with antimicrobial resistance (16% of isolates were extensively drug re-
sistant [XDR]) in the 75 pseudomonads tested [86]. In a comprehensive laboratory study 
by Milojkovic et al. involving 94 isolates—similarly to our study—no correlation was 
noted between antibiotic resistance, genetic composition, pigment production, serotypes, 
and biofilm formation [87]. Cho et al. assessed biofilm formation and MBL carriage in 
carbapenem-resistant P. aeruginosa isolates; the overwhelming majority of isolates (>92%) 
were biofilm producers. Furthermore, the presence of the pslA gene and the MDR pheno-
type all showed positive association with biofilm-forming capacity [88]. Eighty-six P. ae-
ruginosa isolates (involving >31% MDR and >12% XDR), collected from various clinical 
materials, were included in the study of Zahedani et al., where strong correlations were 
found between the expression of efflux pumps and biofilm formation 
(22.47%/21.34%/11.23% were strong/moderate/weak biofilm producers); additionally, the 
presence of some efflux pumps (MexEF-OprN) reduced the virulence of these isolates, 
while others (MexAB-OprM, MexCD-OprJ) did not have the same effect [89]. Rodulfo et 
al. involved n = 176 strains (isolated between 2009 and 2016) in their experiments, showing 
high levels of drug resistance (38.1% MDR), and resistance rates showed strong associa-
tion with the presence of exoU and hemolysin, while negative associations with twitching 
motility [90]. In isolates originating from endotracheal aspirates from ICU patients, Fricks-
Lima et al. found strong and significant correlations between ceftazidime and imipenem-
resistance and strong biofilm-forming capacity [91]. 
Biofilms are characterized by a protective form of growth (essential for survival) in a 
nosocomial environment, which may also maintain an inflammatory environment in vivo 
[91,92]. Nevertheless, it is obvious that the continuous, long-term expression of antibiotic 
resistance-determinants and virulence factors is detrimental for the microorganism’s abil-
ity to adapt to environmental changes [93,94]. For example, in chronic infections, where 
P. aeruginosa establishes long-term persistence in biofilm, the expression of virulence fac-
tors is downregulated, to accommodate for the lower metabolic activity in the exopoly-
saccharide matrix [95]. QS is one of the principal mechanisms responsible for—among 
others—the regulation of virulence factor expression and biofilm formation. QS in Pseu-
domonas consist of a three interconnected systems, namely the Las, Rhl, and Pqs systems; 
these systems facilitate the changes needed for the pathogens’ survival, by the sensing of 
diffusible signal molecules found in their surroundings, which is a proxy for the popula-
tion density in the niche [96–98]. However, many antibiotics also have the ability to affect 
these QS systems in Pseudomonas, either by directly acting on gene expression or by the 
degradation of these signal molecules [99]. The emergence of P. aeruginosa isolates with 
different biofilm-forming capacities may also inform the genetic heterogeneity within 
these species, which is an important factor for successful infection in humans [9]. Never-
theless, differences in the phenotypes and susceptibility trends in these isolates may also 
stem from their different geographical origin and the sampling frame used [100]. The main 
limitation of our study was the reliance on the use of phenotypic methods only during the 
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assessment of the resistance, biofilm-forming, and virulence phenotype of the isolates; 
therefore, we did not have data from molecular methods or on the clonal complexes (CCs) 
for the isolates implicated in the assays. On the other hand, our data are generated from a 
considerably large number of geographically-distinct isolates. 
5. Conclusions 
P. aeruginosa is an opportunistic pathogen, which is often implicated in infectious pa-
thologies, leading to a considerable disease burden worldwide. Along with its intrinsic 
resistance to many antibiotics, Pseudomonas infections are further complicated by the in-
creasing prevalence of carbepenem and colistin non-susceptibility in these strains. Pseu-
domonas species possess many important virulence factors in their repertoire, in addition 
to their propensity to form biofilms (75–100% are biofilm producers). Data on interplay 
between the presence and mechanisms of drug resistance with those of biofilm formation 
and virulence is crucial to address chronic bacterial infections (leading to therapeutic fail-
ure and decreased quality of life in the affected patients), and to provide strategies for 
their management. Our study has showed that isolates with the MDR and non-MDR phe-
notype did not differ significantly in the context of the virulence determinants studied 
(biofilm, various motilities, pyoverdine), with the exception of pyocyanin production. 
Similarly, no statistically-relevant interplay was observed between the individual viru-
lence factors. The latter may either be explained by the adaptation of the microorganism 
to express their virulence factors only in situations where they are necessary for survival, 
or our in vitro methodologies utilized were not sophisticated enough to detect their asso-
ciation. As presented in our paper, many authors have aimed to provide clarity on asso-
ciation between biofilm-forming capacity, virulence factor-expression, and the MDR phe-
notype in P. aeruginosa, but the presently-available results do not yet allow for a conclu-
sion to be made. Additional experiments—preferably involving genomics and/or in vivo 
methods—are needed to provide further clarity and insights into this field. 
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